Compare Citius Pharmaceuticals Inc (CTXR) vs Genuine Parts Company (GPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Genuine Parts Company — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.79M), while Genuine Parts Company trades at $127.56 (market cap $17.29B). The key difference: Genuine Parts Company is far larger — about 1253.8× Citius Pharmaceuticals Inc's market cap, and Genuine Parts Company pays a 3.39% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Genuine Parts Company for 75 Days on average.
| CTXR | GPC | |
|---|---|---|
Market Cap | $13.79M | $17.29B |
Volume | 156,684 | 900,870 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $149.26 |
52-Week Low | $0.48 | $92.47 |
Typical Hold Time | 16 Days | 75 Days |
Enterprise Value | $3.96M | $23.38B |
Dividend Yield | — | 3.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, but remains in a bearish technical trend with negative profitability metrics. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR sales, though net income margin remains deeply negative at -651.27%. Analyst consensus is strongly bullish with 5 buy ratings and a $5.00 price target, representing significant upside potential from current levels.
While CTXR shows promising commercial progress with its oncology drug launch, the stock faces substantial execution risks due to persistent losses and cash burn. The bullish analyst sentiment contrasts with weak fundamentals, creating a high-risk, high-reward scenario for investors betting on successful commercialization of LYMPHIR in the $400M+ CTCL market.
GPC trades at $128.17, up 0.62% today, with a bearish technical signal but neutral oscillators. The company reported mixed earnings, missing in Q4 2025 but beating in Q1 and Q2 2026, with Q3 2026 results due October 20, 2026. Revenue grew to $24.3B in 2025, but net income margin fell sharply to 0.13%. Analyst consensus is a Buy with a $145.75 price target, and the upcoming spinoff of the industrial unit Motion in Q1 2027 is a key catalyst.
The outlook is cautiously optimistic due to the spinoff potential and dividend stability, but risks include declining profitability, high P/E ratio of 501.64, and bearish technical trends. Investors should weigh the long-term benefits of the separation against near-term margin pressures and debt levels rising to 23.08% of assets in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →
